SUMMARY Fear of inducing generalised osteoporosis is one reason why corticosteroids are withheld in patients with rheumatoid arthritis (RA). No studies, however, have directly measured bone density in such patients at clinically relevant sites. To assess this risk we measured bone mineral density in the lumbar spine and femoral neck by dual photon absorptiometry in 84 patients with RA, 44 of whom had been treated with low dose prednis(ol)one (mean dose±SE 8*0O05 mg/day; mean duration of treatment 89*6±12*0 months). There were significant reductions in bone mineral density in patients treated with corticosteroids (lumbar 9-6%, p<OOOl; femoral 12-2%, p<cOOOl) and in those who had not received corticosteroids (lumbar 6-9%, p<OOl; femoral 8X9%, p<OOOl), but the differences between the two groups were not significant. We conclude on the basis of these studies that low dose oral corticosteroids do not increase the risk of generalised osteoporosis in patients with rheumatoid arthritis.
In rheumatoid arthritis (RA), oral corticosteroids are usually reserved for patients with severe disease refractory to other drugs. Although effective in suppressing synovitis, concern about side effects in the long term, such as osteoporosis, have limited their use in uncomplicated RA.1 Some studies have shown that corticosteroids have a significant role in osteoporosis in RA,27 while others have failed to confirm an increased incidence of osteoporosis.811
The reasons for these discrepancies probably relate to differences in the methods used to assess osteoporosis and differences in the patient groups studied, especially with respect to severity of RA 
